TScan Therapeutics/TCRX

$6.82

-1.44%
-
1D1W1MYTD1YMAX

About TScan Therapeutics

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.

Ticker

TCRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Gavin Macbeath

Employees

154

Headquarters

Waltham, United States

TCRX Metrics

BasicAdvanced
$323.36M
Market cap
-
P/E ratio
-$2.49
EPS
-
Beta
-
Dividend rate
$323.36M
$9.00
$1.62
188.01K
6.514
17.698
19.916
-37.87%
-71.29%
-42.07%
15.362
2.14
2.143
55.52%
9.42%
168.7%

What the Analysts think about TCRX

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
70.09% upside
High $15.00
Low $9.00
$6.82
Current price
$11.60
Average price target

TCRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-272.22% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$7.2M
89.47%
Net income
$-19.6M
-14.41%
Profit margin
-272.22%
-54.83%

TCRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 27.59%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.93
-$0.51
-$0.24
-$0.21
-
Expected
-$0.74
-$0.78
-$0.45
-$0.29
-$0.26
Surprise
26.1%
-34.36%
-46.9%
-27.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for TScan Therapeutics stock?

TScan Therapeutics (TCRX) has a market cap of $331.5M as of April 21, 2024.

What is the P/E ratio for TScan Therapeutics stock?

The price to earnings (P/E) ratio for TScan Therapeutics (TCRX) stock is 0 as of April 21, 2024.

Does TScan Therapeutics stock pay dividends?

No, TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next TScan Therapeutics dividend payment date?

TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders.

What is the beta indicator for TScan Therapeutics?

TScan Therapeutics (TCRX) does not currently have a Beta indicator.

What is the TScan Therapeutics stock price target?

The target price for TScan Therapeutics (TCRX) stock is $11.6, which is 70.09% above the current price of $6.82. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell TScan Therapeutics stock

Buy or sell TScan Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing